Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Frontiers in OncologyOpen Access

Bibliometric analysis of immunotherapy for esophageal cancer: 2004-2024

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYunqi HuaYLYubo LiuYLYanhong Liu

Discussion

Loading...

Member takes

Overview

Bibliometric analysis reveals evolving trends and key contributors in immunotherapy for esophageal cancer.

Key Points

  • The study finds a steady increase in publications on immunotherapy for esophageal cancer.
  • China emerges as the leading contributor, with Zhengzhou University being the most productive institution.
  • Immunotherapy is increasingly focusing on tumor microenvironment and immune checkpoint inhibitors.
  • The research emphasizes multimodal treatment strategies to enhance patient outcomes.

Cite This Study

Hua et al. (2025) studied this question.

synapsesocial.com/papers/68bb4df56d6d5674bcd0212ahttps://doi.org/10.3389/fonc.2025.1565132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis2018 · 591 citations
  2. 2Bibliometrics: Methods for studying academic publishing2021 · 1,023 citations
  3. 3Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer2005 · 799 citations
  4. 4Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer2012 · 8,106 citations
  5. 5Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma2013 · 3,431 citations